NasdaqGS - Nasdaq Real Time Price • USD
Prothena Corporation plc (PRTA)
As of 1:32 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 9 | 9 |
| Avg. Estimate | -1.21 | -1.22 | -4.86 | -4.13 |
| Low Estimate | -1.44 | -1.47 | -5.82 | -6.51 |
| High Estimate | -1.12 | -1.09 | -4.38 | -0.49 |
| Year Ago EPS | -1.03 | 0.38 | -2.76 | -4.86 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 9 | 8 |
| Avg. Estimate | 2.17M | 2.17M | 13.35M | 105.31M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | 8.75M | 8.75M | 50M | 300M |
| Year Ago Sales | -- | 84.87M | 91.37M | 13.35M |
| Sales Growth (year/est) | -- | -97.40% | -85.40% | 688.80% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -1 | -0.32 | -1.22 | -1.2 |
| EPS Actual | -1.03 | 0.38 | -1.26 | -1.34 |
| Difference | -0.03 | 0.7 | -0.04 | -0.14 |
| Surprise % | -3.00% | 218.80% | -3.30% | -11.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.21 | -1.22 | -4.86 | -4.13 |
| 7 Days Ago | -1.21 | -1.22 | -4.86 | -4.13 |
| 30 Days Ago | -1.21 | -1.22 | -4.85 | -4.12 |
| 60 Days Ago | -1.22 | -1.23 | -4.98 | -4.13 |
| 90 Days Ago | -1.4 | -1.45 | -4.53 | -4.07 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | PRTA | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -17.50% | -- | -- | 8.50% |
| Next Qtr. | -421.10% | -- | -- | 11.70% |
| Current Year | -76.10% | -- | -- | 5.60% |
| Next Year | 15.00% | -- | -- | 13.20% |
| Next 5 Years (per annum) | 34.07% | -- | -- | 11.07% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight | 4/10/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/13/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 2/20/2024 |
| Maintains | JMP Securities: Market Outperform to Market Outperform | 2/16/2024 |
| Maintains | RBC Capital: Sector Perform to Sector Perform | 2/16/2024 |
| Downgrade | B of A Securities: Buy to Neutral | 1/30/2024 |
Related Tickers
DNLI Denali Therapeutics Inc.
18.87
-0.16%
ZLAB Zai Lab Limited
20.26
+22.24%
ALXO ALX Oncology Holdings Inc.
17.04
+2.59%
ENTA Enanta Pharmaceuticals, Inc.
13.12
+2.78%
RVMD Revolution Medicines, Inc.
37.93
-0.99%
ANAB AnaptysBio, Inc.
25.94
+0.74%
AKRO Akero Therapeutics, Inc.
21.06
+0.17%
APLS Apellis Pharmaceuticals, Inc.
42.01
-0.69%
BBIO BridgeBio Pharma, Inc.
28.32
+2.24%
SWTX SpringWorks Therapeutics, Inc.
43.43
+2.77%